Mechanism of the allantoin fermentation. [electronic resource]
By: Contributor(s): Producer: 19981101Description: 2271-7 p. digitalISSN:- 0021-9258
Publication Type: Journal Article
There are no comments on this title.
-
41
[Thrombocytopenia and thrombocytopathy in neonates and infants].
by Brolíková, D -
42
[Platelet alpha2-adrenergic receptors in essential hypertension. Number of binding sites, cyclic adenosine monophosphate and platelet aggregation].
by Prikryl, P -
43
[Thrombohaemorrhagic syndrome in patients with a myeloproliferative disease with thrombocythemia].
by Penka, M -
44
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
by Halámková, J -
45
Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors.
by Blatny, J -
46
Efficacy and safety of chronic hepatitis C treatment in hemophilic patients.
by Husa, P -
47
[Preparation of patients on anticoagulant treatment for invasive surgery].
by Brejcha, M -
48
Hemocoagulation disorders in extensively burned patients: pilot study for scoring of the DIC.
by Lipový, B -
49
High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
by Aswad, M H -
50
Herpes simplex infection as possible etiology for febrile neutropenia and mucositis in patients treated for hematological malignancies.
by Kubesová, H -
51
Sample processing and methodological pitfalls in multiple myeloma research.
by Potácová, A -
52
[Warning signs preceding the development of septic shock in patients with neutropenia treated for hematologic malignancies].
by Kubesová, H -
53
[Involvement of the cardiac muscle in anemia].
by Elbl, L -
54
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic.
by Salaj, P -
55
[The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
by Penka, M -
56
Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
by Rihova, L -
57
[The preparation of a patient with long-term anticoagulant cumarin treatment for invasive surgery].
by Penka, M -
58
Severe postpartum haemorrhage treated with recombinant activated factor VII in 80 Czech patients: analysis of the UniSeven registry.
by Blatný, J -
59
Biobanking - the First Step to Successful Liquid Biopsy Experiments.
by Almasi, M -
60
Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy.
by Ocadlikova, Darina
Mechanism of the allantoin fermentation.
APA
VALENTINE R. C., BOJANOWSKI R., GAUDY E. & WOLFE R. S. (19981101). Mechanism of the allantoin fermentation. : The Journal of biological chemistry.
Chicago
VALENTINE R C, BOJANOWSKI R, GAUDY E and WOLFE R S. 19981101. Mechanism of the allantoin fermentation. : The Journal of biological chemistry.
Harvard
VALENTINE R. C., BOJANOWSKI R., GAUDY E. and WOLFE R. S. (19981101). Mechanism of the allantoin fermentation. : The Journal of biological chemistry.
MLA
VALENTINE R C, BOJANOWSKI R, GAUDY E and WOLFE R S. Mechanism of the allantoin fermentation. : The Journal of biological chemistry. 19981101.